Bristol-Myers Squibb India
Bristol-Myers Squibb India is a subsidiary of Bristol-Myers Squibb — a
global biopharmaceutical company headquartered in New York City. Our
mission is to to discover, develop and deliver innovative medicines that
help patients prevail over serious diseases.
At Bristol-Myers Squibb, we take our mission to extend and enhance human life
seriously. Since 2002, we have introduced nine new products to the global market
for the treatment of psychiatric disorders, cancer, HIV, chronic hepatitis B,
rheumatoid arthritis and other serious diseases. Two of these medications are
biologic products. In the fight against serious disease, biologics — or
protein-derived therapies — are playing an increasingly prominent role. In
addition, other biologic compounds, as well as scores of additional
investigational medicines are advancing through our pharmaceutical development
pipeline to address unmet medical need in diseases such as cardiovascular
disease, solid organ transplant rejection, Alzheimer’s disease and obesity.
Bristol- Myers Squibb is recognized as having one of the most productive
pipelines in the industry.
Bristol-Myers Squibb commenced current operations in India in 2004 with a
strategy closely aligned to its global focus: to fulfill unmet medical needs.
Today, more than 100 employees work at the company’s headquarters in Mumbai.
Growth in India continues to gain momentum with the company’s recent
announcement to expand Research and Development (R&D) capabilities in India. The
company is increasing the scope of its relationship with Biocon Limited, India’s
premier biotech company, and expanding its relationship with Accenture, a global
management consulting, technology services and outsourcing company.
Our Commitment in India
As part of the company’s strategy to transform to a next-generation
BioPharma leader, Bristol-Myers Squibb established an R&D presence in
Asia. India was chosen partly due to factors such as access to a large
pool of skilled and knowledgeable talent, high-quality standards of
academic research, increased commitment to protecting intellectual
property (IP) rights, conducive infrastructure, established
capabilities, committed work ethics, and a productive labor market.